18/10/2022 - 17:09

Radiopharm prepares to take cancer treatment to FDA

18/10/2022 - 17:09


Save articles for future reference.

Medical technology specialist Radiopharm Theranostics is gearing up to approach the powerful US Federal Food and Drug Administration, or “FDA” to get its cancer treatment known as “Pivalate” to market after successfully concluding a phase II clinical trial in the UK. The trial indicated that Pivalate can detect and monitor secondary brain tumours regardless of the origin of the primary cancer.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options